Were N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
| Registrars: |
Capita Registrars |
| CEO: |
David H Solomon |
| Executive Director: |
Luke Cairns |
| Independent Non-Executive Director: |
Alastair Smith |
| Non-Executive Chairman: |
Chris Britten |
| Non-Executive Director: |
Michael Palfreyman, Edward Wardle |
| Address: |
2 Portman Street, London, United Kingdom |
| Phone: |
|
| Fax: |
|
| Website: |
http://www.n4pharma.com/ |
| Email: |
|